Stocks Health care DARE
NASDAQ · Health careDare Bioscience, Inc. (DARE)
It posted a net loss of $11M. In fiscal 2025 capital spending exceeded operating cash flow by $10.3M. At June 30, 2026 it held $12.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Dare Bioscience, Inc.
- Net worth
- Dare Bioscience, Inc. has a market value (market cap) of $10.6M at the latest share price, and shareholders' equity of -$560.1K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1M (+10,429.4% year on year), with a net loss of $13.4M.
- Cash flow
- In fiscal 2025 operations used $9.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Dare Bioscience, Inc.'s next report was expected around October 22, 2026 and is not on file with the SEC yet.
What Dare Bioscience, Inc. does
Dare Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DARE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1M | -$13.4M | -$1.20 | -$10.3M |
| 2024 | $9.8K | -$4.1M | -$0.48 | $4.9M |
| 2023 | $2.8M | -$30.2M | -$4.15 | -$39.5M |
| 2022 | $10M | -$30.9M | -$4.39 | -$18.2M |
| 2021 | $0 | -$38.7M | -$7.47 | -$28.8M |
| 2020 | n/a | -$27.4M | -$10.79 | -$25.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where DARE ranks in Health care
Latest SEC filings
What Dare Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Proxy statement DEF 14A
- October 2, 2026
- October 1, 2026
- September 23, 2026Preliminary proxy statement PRE 14A
- September 11, 2026
- September 9, 2026
- August 28, 2026Passive stake (5% or more) SCHEDULE 13G
- August 26, 2026IPO registration S-1
- August 24, 2026Passive stake (5% or more) SCHEDULE 13G
- August 19, 2026Form 253G2 filing 253G2
Insider trades
What the people running Dare Bioscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Steele Robin JoanDirector | Received as pay | 26,540 | - |
| June 30, 2026 | Rastetter William HDirector | Received as pay | 38,862 | - |
| June 30, 2026 | Matz Gregory WDirector | Received as pay | 30,805 | - |
| June 30, 2026 | Kelley Susan L.Director | Received as pay | 23,696 | - |
| June 30, 2026 | Grossman Jessica D.Director | Received as pay | 26,066 | - |
Who owns DARE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Law Custodial Inc.13G, passive | 15.9% | October 6, 2025 |
| L1 Capital Global Opportunities Master Fund, Ltd.13G, passive | 9.99% | August 24, 2026 |
| Lind Global Fund III LP13G, passive with 2 related filers | 5.65% | August 28, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 167,385 shares in total, about $115.8K at the last price.
| Holder | Shares |
|---|---|
| Steele Robin JoanDirector | 47,055 |
| Rastetter William HDirector | 39,721 |
| Matz Gregory WDirector | 30,847 |
| Grossman Jessica D.Director | 26,066 |
| Kelley Susan L.Director | 23,696 |
Questions about DARE
What does Dare Bioscience, Inc. do?
Dare Bioscience, Inc. is a company in the Health care sector, listed on NASDAQ as DARE. Its shares trade on NASDAQ under the ticker DARE.
What is Dare Bioscience, Inc.'s net worth?
Dare Bioscience, Inc. has a market value (market cap) of $10.6M at the latest share price, and shareholders' equity of -$560.1K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Dare Bioscience, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11M.
When did Dare Bioscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from October 6, 2026.
When is Dare Bioscience, Inc.'s next earnings report?
Dare Bioscience, Inc.'s next report was expected around October 22, 2026 and is not on file with the SEC yet.
Similar companies
Compare DARE with
Follow DARE
Get an email when Dare Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Dare Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.